Roche Holding AG said a high-dose version of Ocrevus, its best-selling multiple sclerosis drug, failed to outperform the original in a large study, potentially reducing the drugmaker’s ability ...
Roche said a trial for its multiple-sclerosis drug Ocrevus failed to meet its primary endpoint in showing additional benefit in slowing disability progression with a higher dose. The Swiss ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback